58 studies found for:    "Carcinoid syndrome"
Show Display Options
Rank Status Study
1 Withdrawn Study of Panitumumab in the Treatment of Carcinoid Syndrome
Condition: Carcinoid Syndrome
Intervention: Drug: Panitumumab
2 Completed Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome
Condition: Symptoms of Carcinoid Syndrome
Interventions: Drug: Low Dose LX1606 - Day 1 (start);   Drug: Mid-low dose LX1606 - Day 15 (start);   Drug: Mid-high dose LX1606 - Day 29 (start);   Drug: High dose LX1606 - Day 43 (start);   Drug: 4-Week Open Label Dose Extension;   Drug: 72-Week Open Label Dose Extension
3 Terminated Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome
Condition: Malignant Carcinoid Syndrome
Interventions: Drug: lanreotide Autogel (somatostatin analogue);   Drug: Sandostatin long acting release (LAR) Depot (somatostatin analogue)
4 Completed Effects of Serotonin Excess on Bone in Carcinoid Syndrome
Condition: Carcinoid Syndrome
Intervention:
5 Recruiting Telotristat Etiprate for Carcinoid Syndrome Therapy
Condition: Carcinoid Syndrome
Interventions: Drug: Telotristat etiprate tablets (250 mg);   Drug: Placebo
6 Terminated Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome
Condition: Carcinoid Syndrome
Intervention: Drug: Octreotide
7 Active, not recruiting An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome
Condition: Carcinoid Syndrome
Interventions: Drug: Somatuline Depot (lanreotide);   Drug: placebo
8 Terminated Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome
Condition: Carcinoid Syndrome
Intervention: Drug: BIM 23A760
9 Recruiting TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)
Condition: Carcinoid Syndrome
Interventions: Drug: Telotristat etiprate tablets (250 mg);   Drug: Placebo tablets
10 Completed A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea
Condition: Neuroendocrine Tumour (NET) With Carcinoid Syndrome
Intervention:
11 Recruiting Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
Condition: Carcinoid Syndrome
Intervention: Drug: Telotristat etiprate tablets (250 mg)
12 Completed Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy
Condition: Carcinoid Syndrome
Interventions: Drug: Low Dose Part 1;   Drug: Mid-Low Dose Part 1;   Drug: Mid-High Dose Part 1;   Drug: High Dose Part 1;   Drug: Part 2 Expanded Cohort;   Drug: Placebo;   Drug: Open Label Dose Extension;   Drug: Open Label Extension 2;   Drug: Open Label Extension 3
13 Completed An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males
Condition: Carcinoid Syndrome
Intervention: Drug: 500 mg [14C]-LX1606
14 Completed
Has Results
Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor
Conditions: Carcinoid Tumor;   Malignant Carcinoid Syndrome
Interventions: Drug: Octreotide;   Drug: Placebo;   Drug: Everolimus
15 Active, not recruiting P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome
Condition: Neuroendocrine Carcinoma
Intervention: Drug: Octreotide LAR
16 Completed Azilect + Antidepressant Chart Review
Condition: Serotonin Syndrome
Interventions: Drug: Group R+AD Rasagiline + Antidepressant;   Drug: Group R Rasagiline;   Drug: Group AD Anti-PD + Antidepressant
17 Terminated Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Metastatic Gastrointestinal Carcinoid Tumor;   Pancreatic Polypeptide Tumor;   Pulmonary Carcinoid Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Regional Gastrointestinal Carcinoid Tumor;   Somatostatinoma
Interventions: Drug: romidepsin;   Other: laboratory biomarker analysis
18 Withdrawn Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors
Conditions: Gastrointestinal Carcinoid Tumor;   Islet Cell Carcinoma
Interventions: Drug: octreotide acetate;   Drug: vatalanib;   Procedure: anti-cytokine therapy;   Procedure: antiangiogenesis therapy;   Procedure: biological  therapy;   Procedure: endocrine therapy;   Procedure: enzyme inhibitor therapy;   Procedure: growth factor antagonist therapy;   Procedure: hormone therapy;   Procedure: protein tyrosine kinase inhibitor therapy;   Procedure: somatostatin analogue therapy
19 Active, not recruiting Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Conditions: Pulmonary Carcinoid Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Renal Cell Cancer;   Recurrent Uterine Sarcoma;   Stage III Renal Cell Cancer;   Stage IIIB Uterine Sarcoma;   Stage IIIC Uterine Sarcoma;   Stage IV Renal Cell Cancer;   Stage IVA Uterine Sarcoma;   Stage IVB Uterine Sarcoma;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: trebananib;   Drug: temsirolimus;   Other: pharmacological study;   Other: laboratory biomarker analysis
20 Completed Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma
Conditions: Metastatic Gastrointestinal Carcinoid Tumor;   Pulmonary Carcinoid Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma
Interventions: Drug: temsirolimus;   Other: laboratory biomarker analysis

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years